Osteoporosis Modelpreferred Osteoporosis Model,the Osteoarthritis Modelleading brand

   Osteoporosis Modelx2a3868enandPDX Modelof PharmaLegacy Laboratories (Shanghai) Co., Ltdis favored by the majority of customers love, We have established long-term cooperation with many partner, Liver Fibrosis Model,CDX Modelfrom PharmaLegacymeet the needs of our customers. PharmaLegacystrength,abide by contract, keep faith, take quality and credit of contract,obtained the customer trust and praise.

   PharmaLegacy Laboratories (Shanghai) Co., Ltd has been devoted to study the needs of PharmaLegacy industrial customers, ant tailored to customers demand and solutions. The advantage of PharmaLegacy lies not only in the industry-leading technology and the elite professional team, but also to provide excellent services in Pharmacodynamic evaluation test platform,humanized animal model,antibody research and development servi,and the enthusiasm of positive innovation and faith of respect promise . Become a customer trusted Good quality Osteoporosis Model integrated service providers, to help customers realize the business value of Osteoporosis Model, is PharmaLegacy unswerving mission and pursuit. Details: Bone provides protection to visceral organs, storage of minerals, locomotive movement and are the locations of hematopoiesis. Structural integrity of bone can be affected by factors of aging, dietary imbalance, disuse, environmental contamination, infections, medicine, metabolic disorders, physical loading, radiation, smoking and trauma. Efficacy and safety data of the developing therapeutics to osteoporosis model is required to predict the effects in human for excluding the toxicity of it. Bone fragility increases with age in both genders, and most notably after menopause in female. Anti-resorptive agents are well established, such as bisphosphonates, SERMs and likely anti-RANKL antibodies. Anabolic agents are actively being developed. Besides PTH analogues and stem cells, molecules from BMP family and Wnt signal pathways, such as Smads, ERK, Dkk-1, Runx2, and beta-catenin are targets for therapeutics. Safety and efficacy data of osteoporosis model (rodents and non-human primates) are required to predict the therapeutic effects in human.

    With the purpose of Quality first, service is paramount in PharmaLegacy, our strict product quality control system ensures that Non-Human Primates models,DMPK and other products of high quality and stability. We have a first-class laboratory equipment and a highly experienced professional and technical team. In the future, we will continue to work hard and get win-win cooperation for a better tomorrow! For more information, please visit the official website: www.pharmalegacy.com